Research summary ·
CRISPR Gene Editing for Nucleotide Repeat Expansion Disorders: A Systematic Review of Preclinical and Clinical Evidence.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review looked at CRISPR gene editing. It was for disorders caused by DNA repeats that grow too long (NREDs). These include DMD (Duchenne muscular dystrophy) and HD (Huntington's disease). DM1 (myotonic dystrophy type 1) is also included. The review covers lab data. It looked at how well CRISPR works, its effects on molecules and its limits. The team searched PubMed, Scopus and Embase up to June 2025. It followed PRISMA 2020 guidelines. It kept studies of CRISPR-Cas systems in human-derived models grown in the lab. Study quality was scored with a tool for non-randomized studies. Data were summarized in words, not pooled.
What they found
6510 records were screened. A set of studies was included. Most targeted DMD (n = 9), HD (n = 6) or DM1 (n = 3). They used patient-derived stem cells or muscle and nerve cells. Cas9 from Streptococcus pyogenes was used most often. Some studies used engineered Cas9 or dCas9 fusion proteins to control gene activity. Delivery used viral vectors, such as adeno-associated virus and lentivirus. It also used nonviral routes, such as plasmid, lipofection and electroporation. Studies saw uniform genome editing, transcript rescue and protein restoration. Splicing correction and dystrophin restoration were shown. Flaws limited the strength of the work. These were no blinding, no follow-up and poor reporting of off-target effects.
What it means for patients
The paper says CRISPR-Cas systems give repeatable molecular and functional correction in NRED models. It says they have translational potential. It says stronger methods and full safety profiling are still needed. It says in vivo checks are also needed before clinical translation.
Why it is not certain yet
The paper says flaws limited the strength of the work. The data come from human-derived cells in the lab. A review can only be as good as the studies in it.
Source
CRISPR Gene Editing for Nucleotide Repeat Expansion Disorders: A Systematic Review of Preclinical and Clinical Evidence.
PubMed · PMID 41840824We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Myotonic dystrophy publications